VRNI
MCID: VTR013
MIFTS: 50

Vitreoretinopathy, Neovascular Inflammatory (VRNI) malady

Categories: Genetic diseases, Eye diseases, Rare diseases

Aliases & Classifications for Vitreoretinopathy, Neovascular Inflammatory

Aliases & Descriptions for Vitreoretinopathy, Neovascular Inflammatory:

Name: Vitreoretinopathy, Neovascular Inflammatory 54 24 66 29 13
Proliferative Vitreoretinopathy 12 24 66 14 69
Adniv 56 66
Vrni 24 66
Pvr 24 66
Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy 56
Neovascular Inflammatory Vitreoretinopathy Autosomal Dominant 66
Vitreoretinopathy, Proliferative 42
Proliferative Vitreo-Retinopathy 69
Vitreoretinopathy Proliferative 52
Retinitis Proliferans 12

Characteristics:

Orphanet epidemiological data:

56
autosomal dominant neovascular inflammatory vitreoretinopathy
Inheritance: Autosomal dominant; Prevalence: <1/1000000 (Worldwide); Age of onset: All ages;

HPO:

32
vitreoretinopathy, neovascular inflammatory:
Inheritance autosomal dominant inheritance


Classifications:

Orphanet: 56  
Rare eye diseases


External Ids:

OMIM 54 193235
Disease Ontology 12 DOID:9719
MeSH 42 D018630
SNOMED-CT 64 193364004 232016005
Orphanet 56 ORPHA329211
ICD10 via Orphanet 34 H35.2
MedGen 40 C1860404
UMLS 69 C0242852

Summaries for Vitreoretinopathy, Neovascular Inflammatory

UniProtKB/Swiss-Prot : 66 Vitreoretinopathy, neovascular inflammatory: An autoimmune condition of the eye that sequentially mimics uveitis, retinitis pigmentosa, and proliferative diabetic retinopathy as it progresses to complete blindness. Patients present during the second or third decade of life with posterior uveitis and reduction of the electroretinogram b-wave. They become more symptomatic when cataracts, cystoid macular edema, and disk edema diminish visual acuity during the second stage. Severe vision loss begins during the third stage when proliferative retinal neovascularization and epiretinal membranes appear. There is an ongoing pigmentary retinal degeneration and peripheral visual field loss during all stages. In the fourth stage, proliferative vitreoretinopathy causes tractional retinal detachments at the macula and vitreous base. The fifth or end-stage disease is marked by phthisis.

MalaCards based summary : Vitreoretinopathy, Neovascular Inflammatory, also known as proliferative vitreoretinopathy, is related to poliomyelitis and paralytic poliomyelitis, and has symptoms including blindness, abnormal electroretinogram and retinal detachment. An important gene associated with Vitreoretinopathy, Neovascular Inflammatory is CAPN5 (Calpain 5), and among its related pathways/superpathways are Apoptotic Pathways in Synovial Fibroblasts and ERK Signaling. The drugs Triamcinolone and Bupivacaine have been mentioned in the context of this disorder. Affiliated tissues include eye and retina, and related phenotypes are homeostasis/metabolism and cardiovascular system

OMIM : 54 Autosomal dominant neovascular inflammatory vitreoretinopathy (ADNIV) is a blinding disorder that shares some clinical... (193235) more...

Related Diseases for Vitreoretinopathy, Neovascular Inflammatory

Diseases related to Vitreoretinopathy, Neovascular Inflammatory via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 73)
id Related Disease Score Top Affiliating Genes
1 poliomyelitis 11.0
2 paralytic poliomyelitis 11.0
3 pericardium disease 10.9
4 heart conduction disease 10.9
5 cardiac tamponade 10.9
6 pericardial effusion 10.9
7 urethral diverticulum 10.9
8 enterocele 10.9
9 prolapse of female genital organ 10.9
10 basilar artery insufficiency 10.9
11 ovarian cystic teratoma 10.9
12 bile acid synthesis defect, congenital, 2 10.8
13 cleft lip/palate-ectodermal dysplasia syndrome 10.8
14 total anomalous pulmonary venous return 10.8
15 andersen syndrome 10.8
16 congenital bile acid synthesis defect 10.8
17 retinitis 10.8
18 retinal detachment 10.7
19 endotheliitis 10.2
20 hyperinsulinism 10.2 GFAP TGFB2
21 miliaria 10.2 CTGF TGFB1
22 geleophysic dysplasia 2 10.2 CTGF TGFB1 TGFB2
23 hypogonadotropic hypogonadism 16 with or without anosmia 10.2 HGF MET
24 anterograde amnesia 10.1 CAPN5 FGF2 GFAP
25 autosomal dominant nonsyndromic deafness 6 10.1 HGF MET
26 bladder diffuse clear cell adenocarcinoma 10.1 FGF2 TGFB1
27 connective tissue cancer 10.1 FGF2 GFAP TGFB1
28 adult infiltrating astrocytic neoplasm 10.1 ADM CCL2 TGFB2
29 oppositional defiant disorder 10.1 CCL2 FGF2 HGF
30 hypertrichosis of eyelid 10.1 CCL2 CTGF TGFB1
31 pulmonary valve insufficiency 10.1 CCL2 CTGF TGFB1
32 acute necrotizing encephalitis 10.1 CCL2 CTGF TGFB1
33 malignant neoplasm of acoustic nerve 10.0 CCL2 CTGF TGFB1
34 adult central nervous system primitive neuroectodermal neoplasm 10.0 HGF MET
35 zika fever 10.0 CTGF TGFB1 TIMP1
36 cholera 10.0 CTGF TGFB1 TIMP1
37 calcinosis 10.0 CCL2 CTGF TGFB1
38 neuroectodermal endocrine syndrome 10.0 CTGF TGFB1 TIMP1
39 germ cell and embryonal cancer 10.0 CTGF TGFB1 TIMP1
40 cataract 10.0
41 hemorrhagic cystitis 10.0 CCL2 CTGF HGF TGFB1
42 neuromyelitis optica 9.9 FGF2 TGFB1 TIMP1
43 anal neuroendocrine tumor 9.9 HGF MET
44 patent foramen ovale 9.9 CTGF HGF TGFB1 TIMP1
45 epidermolysis bullosa simplex, sutosomal recessive 2 9.9 CCL2 CTGF FGF2 HGF TGFB2
46 choroiditis 9.9
47 bone angioendothelial sarcoma 9.9 CCL2 TGFB1 TIMP1
48 mental retardation, autosomal recessive 40 9.9 CTGF FGF2 SPARC
49 lymphoblastic lymphoma 9.9 CTGF HGF TGFB1 TIMP1
50 hyperuricemia, pulmonary hypertension, renal failure, and alkalosis 9.9 ADM CCL2 TIMP1

Graphical network of the top 20 diseases related to Vitreoretinopathy, Neovascular Inflammatory:



Diseases related to Vitreoretinopathy, Neovascular Inflammatory

Symptoms & Phenotypes for Vitreoretinopathy, Neovascular Inflammatory

Symptoms by clinical synopsis from OMIM:

193235

Clinical features from OMIM:

193235

Human phenotypes related to Vitreoretinopathy, Neovascular Inflammatory:

32 (show all 9)
id Description HPO Frequency HPO Source Accession
1 blindness 32 HP:0000618
2 abnormal electroretinogram 32 HP:0000512
3 retinal detachment 32 HP:0000541
4 uveitis 32 HP:0000554
5 vitreoretinopathy 32 HP:0007773
6 vitreous hemorrhage 32 HP:0007902
7 large hyperpigmented retinal spots 32 HP:0007658
8 posterior retinal neovascularization 32 HP:0007778
9 peripheral retinal neovascularization 32 HP:0030667

MGI Mouse Phenotypes related to Vitreoretinopathy, Neovascular Inflammatory:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.11 ADM CTGF FGF1 FGF2 GFAP MET
2 cardiovascular system MP:0005385 10.09 HGF MET TGFB1 TGFB2 TIMP1 ADM
3 hematopoietic system MP:0005397 10.06 TGFB1 TGFB2 TIMP1 VTN ADM FGF1
4 immune system MP:0005387 9.97 ADM CAPN5 CCL2 GFAP MET SPARC
5 mortality/aging MP:0010768 9.96 ADM CAPN5 CTGF FGF2 GFAP HGF
6 muscle MP:0005369 9.63 ADM FGF2 GFAP MET TGFB1 TGFB2
7 respiratory system MP:0005388 9.43 ADM TIMP1 CTGF MET TGFB1 TGFB2
8 vision/eye MP:0005391 9.17 CTGF FGF2 GFAP MET SPARC TGFB1

Drugs & Therapeutics for Vitreoretinopathy, Neovascular Inflammatory

Drugs for Vitreoretinopathy, Neovascular Inflammatory (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 45)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Triamcinolone Approved, Vet_approved Phase 4,Phase 3 124-94-7 31307
2
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
3
Isotretinoin Approved Phase 4 4759-48-2 5538 5282379
4 triamcinolone acetonide Phase 4,Phase 3
5 glucocorticoids Phase 4,Phase 3
6 Hormone Antagonists Phase 4,Phase 3
7 Triamcinolone diacetate Phase 4,Phase 3
8 Triamcinolone hexacetonide Phase 4,Phase 3
9 Hormones Phase 4,Phase 3
10 Peripheral Nervous System Agents Phase 4,Phase 3
11 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3
12 Anti-Inflammatory Agents Phase 4,Phase 3
13 Dermatologic Agents Phase 4
14 Anesthetics Phase 4
15 Anesthetics, Local Phase 4
16 Immunosuppressive Agents Phase 4,Phase 3
17 Central Nervous System Depressants Phase 4
18
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
19
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
20
Colchicine Approved Phase 3 64-86-8 6167 2833
21
Dalteparin Approved Phase 3 9041-08-1
22
Fluorouracil Approved Phase 3 51-21-8 3385
23
Vitamin C Approved, Nutraceutical Phase 3 50-81-7 5785 54670067
24 calcium heparin Phase 3
25 Dexamethasone acetate Phase 3 1177-87-3
26
protease inhibitors Phase 3
27 Gastrointestinal Agents Phase 3
28 HIV Protease Inhibitors Phase 3
29 Heparin, Low-Molecular-Weight Phase 3
30 Dexamethasone 21-phosphate Phase 3
31 Fibrinolytic Agents Phase 3
32 Anticoagulants Phase 3
33 Antiemetics Phase 3
34 Antimitotic Agents Phase 3
35 Antirheumatic Agents Phase 3
36 BB 1101 Phase 3
37 Autonomic Agents Phase 3
38 Antineoplastic Agents, Hormonal Phase 3
39 Calcium, Dietary Phase 3
40 Pharmaceutical Solutions Phase 3
41 Antimetabolites Phase 3
42 Antimetabolites, Antineoplastic Phase 3
43
Bevacizumab Approved, Investigational Phase 2 216974-75-3
44 Angiogenesis Inhibitors Phase 2
45 Angiogenesis Modulating Agents Phase 2

Interventional clinical trials:

(show all 19)
id Name Status NCT ID Phase
1 Isotretinoin for Proliferative Vitreoretinopathy Completed NCT01445028 Phase 4
2 Postoperative Pain Control Following Vitreoretinal Surgery Completed NCT01995045 Phase 4
3 Oral Colchicine Combined With Intravitreal Infusion of Dexamethasone, LMW Heparin and 5-FU for Management of Proliferative Vitreoretinopathy (PVR) Unknown status NCT00370760 Phase 3
4 Efficacy of Oral Colchicine in Prevention of Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment Unknown status NCT00370201 Phase 3
5 The Effect of 5-FU and LMW Heparin on the Rate of Retinal Redetachment After Silicone Oil Removal in Cases of PVR Unknown status NCT00371020 Phase 3
6 Comparison High-Density Silicone Oils in Retinal Detachment Unknown status NCT00403702 Phase 2, Phase 3
7 Surgical Management of Pseudophakic and Aphakic Retinal Detachment; a Randomized Clinical Trial Unknown status NCT00370279 Phase 3
8 Triamcinolone Acetonide in Silicone-Filled Eyes as Adjunctive Treatment for Proliferative Vitreoretinopathy Completed NCT00373282 Phase 3
9 The Silicone Study Completed NCT00000140 Phase 3
10 Prophylactic Intravitreal 5-Fluorouracil and Heparin to Prevent PVR in High-risk Patients With Retinal Detachment. Recruiting NCT02834559 Phase 3
11 Adjunctive Steroid Combination in Ocular Trauma (ASCOT) Study Recruiting NCT02873026 Phase 3
12 Bevacizumab Against Recurrent Retinal Detachment Unknown status NCT02192970 Phase 2
13 Dacorin for Proliferative Vitreoretinopathy Completed NCT02865031 Phase 1, Phase 2
14 Comparison of Two Techniques for Epiretinal or Internal Limiting Membrane Peel Unknown status NCT00892619
15 Comparative Study of 1000 Centistoke Versus 5000 Centistoke Silicone Oil for Repair of Complex Retinal Detachments Completed NCT01255293
16 Eye Injections of Bevacizumab for Lowering Risk of Scar Tissue in the Retina and Repeated Retinal Detachment. Completed NCT01860586
17 Double Endotamponade With Perfluorodecalin and Silicone Oil in Retinal Detachment Surgery. Recruiting NCT01959568
18 Optical Coherence Tomography - Rescan During Dissection of Macular Membranes Not yet recruiting NCT02748421
19 Pneumatic Retinopexy Versus Vitrectomy for Retinal Detachment in Patients With Extended Criteria Not yet recruiting NCT02871531

Search NIH Clinical Center for Vitreoretinopathy, Neovascular Inflammatory

Cochrane evidence based reviews: vitreoretinopathy, proliferative

Genetic Tests for Vitreoretinopathy, Neovascular Inflammatory

Genetic tests related to Vitreoretinopathy, Neovascular Inflammatory:

id Genetic test Affiliating Genes
1 Vitreoretinopathy, Neovascular Inflammatory 29 24 CAPN5

Anatomical Context for Vitreoretinopathy, Neovascular Inflammatory

MalaCards organs/tissues related to Vitreoretinopathy, Neovascular Inflammatory:

39
Eye, Retina

Publications for Vitreoretinopathy, Neovascular Inflammatory

Variations for Vitreoretinopathy, Neovascular Inflammatory

UniProtKB/Swiss-Prot genetic disease variations for Vitreoretinopathy, Neovascular Inflammatory:

66
id Symbol AA change Variation ID SNP ID
1 CAPN5 p.Arg243Leu VAR_069277 rs397514601
2 CAPN5 p.Leu244Pro VAR_069278 rs397514602

ClinVar genetic disease variations for Vitreoretinopathy, Neovascular Inflammatory:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 CAPN5 NM_004055.4(CAPN5): c.728G> T (p.Arg243Leu) single nucleotide variant Pathogenic rs397514601 GRCh37 Chromosome 11, 76826469: 76826469
2 CAPN5 NM_004055.4(CAPN5): c.731T> C (p.Leu244Pro) single nucleotide variant Pathogenic rs397514602 GRCh37 Chromosome 11, 76826472: 76826472

Expression for Vitreoretinopathy, Neovascular Inflammatory

Search GEO for disease gene expression data for Vitreoretinopathy, Neovascular Inflammatory.

Pathways for Vitreoretinopathy, Neovascular Inflammatory

Pathways related to Vitreoretinopathy, Neovascular Inflammatory according to GeneCards Suite gene sharing:

(show all 45)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.77 CTGF FGF1 FGF2 HGF MET TGFB1
2
Show member pathways
13.76 CAPN5 CCL2 CTGF FGF1 FGF2 GFAP
3
Show member pathways
13.64 CTGF FGF1 FGF2 HGF MET TGFB1
4
Show member pathways
13.48 CTGF FGF1 FGF2 HGF MET TGFB1
5
Show member pathways
13.48 CCL2 CTGF FGF1 FGF2 HGF MET
6
Show member pathways
13.32 CCL2 CTGF FGF1 FGF2 HGF MET
7
Show member pathways
13.3 CCL2 FGF1 FGF2 HGF MET TGFB1
8
Show member pathways
13.27 CTGF FGF1 FGF2 HGF MET TGFB1
9
Show member pathways
13.23 CTGF FGF1 FGF2 HGF MET TGFB1
10
Show member pathways
13.17 CCL2 CTGF FGF1 FGF2 HGF MET
11
Show member pathways
12.99 CTGF FGF1 FGF2 HGF MET TGFB1
12
Show member pathways
12.79 CCL2 CTGF FGF1 FGF2 HGF MET
13
Show member pathways
12.68 CAPN5 FGF2 SPARC TGFB1 TGFB2 TIMP1
14 12.64 FGF1 FGF2 HGF MET TGFB1 TGFB2
15 12.62 FGF1 FGF2 TGFB1 TGFB2
16 12.55 FGF1 FGF2 HGF MET VTN
17
Show member pathways
12.38 CTGF FGF1 FGF2 HGF MET TGFB1
18 12.19 FGF2 HGF MET TGFB1 TGFB2 VTN
19 12.11 CTGF FGF1 TGFB1 TGFB2
20 12.04 FGF2 HGF MET TGFB1
21 12.03 HGF TGFB1 TGFB2
22 12.02 FGF1 FGF2 MET
23 11.97 CCL2 FGF2 HGF TGFB1 TIMP1
24 11.94 CCL2 GFAP TGFB1
25 11.89 FGF2 SPARC TGFB1 TGFB2
26 11.88 SPARC TGFB1 VTN
27 11.84 CCL2 TGFB1 TGFB2
28 11.8 CCL2 TGFB1 TGFB2
29
Show member pathways
11.7 TGFB1 TGFB2 VTN
30
Show member pathways
11.66 FGF2 TGFB1 VTN
31 11.64 FGF2 TGFB1 TGFB2
32 11.61 SPARC TIMP1 VTN
33 11.61 SPARC TGFB1 TGFB2 VTN
34 11.6 CTGF FGF1 FGF2 HGF TGFB1 TGFB2
35 11.52 FGF1 FGF2 HGF TGFB1
36 11.5 FGF2 TGFB1 TGFB2
37 11.48 FGF1 HGF MET
38 11.44 CCL2 FGF1 FGF2 HGF TGFB1 TGFB2
39 11.41 CCL2 HGF MET TGFB1 TGFB2
40 11.21 HGF MET TGFB1 TGFB2
41 11.01 TGFB1 TGFB2
42 11 HGF MET TGFB1
43 10.97 CCL2 CTGF FGF1 FGF2 HGF TGFB1
44 10.96 CCL2 TIMP1
45 10.85 TGFB1 TGFB2

GO Terms for Vitreoretinopathy, Neovascular Inflammatory

Cellular components related to Vitreoretinopathy, Neovascular Inflammatory according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 proteinaceous extracellular matrix GO:0005578 9.73 CTGF FGF1 SPARC TGFB1 TIMP1 VTN
2 extracellular region GO:0005576 9.73 ADM CCL2 CTGF FGF1 FGF2 HGF
3 extracellular matrix GO:0031012 9.67 TGFB1 TGFB2 TIMP1 VTN
4 platelet alpha granule lumen GO:0031093 9.55 HGF SPARC TGFB1 TGFB2 TIMP1
5 basement membrane GO:0005604 9.5 SPARC TIMP1 VTN
6 extracellular space GO:0005615 9.36 ADM CCL2 CTGF FGF1 FGF2 HGF

Biological processes related to Vitreoretinopathy, Neovascular Inflammatory according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
id Name GO ID Score Top Affiliating Genes
1 heart development GO:0007507 9.95 ADM SPARC TGFB1 TGFB2
2 extracellular matrix organization GO:0030198 9.93 FGF2 SPARC TGFB2 VTN
3 response to hypoxia GO:0001666 9.91 ADM CCL2 TGFB1 TGFB2
4 peptidyl-tyrosine phosphorylation GO:0018108 9.91 FGF1 FGF2 HGF MET
5 angiogenesis GO:0001525 9.89 CCL2 CTGF FGF1 FGF2 TGFB2
6 activation of MAPK activity GO:0000187 9.87 FGF1 FGF2 HGF
7 lung development GO:0030324 9.87 CTGF FGF1 SPARC
8 response to organic substance GO:0010033 9.86 ADM TGFB1 TIMP1
9 transforming growth factor beta receptor signaling pathway GO:0007179 9.85 CCL2 TGFB1 TGFB2
10 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.85 HGF TGFB1 VTN
11 positive regulation of angiogenesis GO:0045766 9.85 ADM FGF1 FGF2 HGF
12 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.85 CCL2 CTGF FGF1 FGF2 TGFB1
13 fibroblast growth factor receptor signaling pathway GO:0008543 9.84 CTGF FGF1 FGF2
14 neural tube closure GO:0001843 9.84 ADM TGFB1 TGFB2
15 phosphatidylinositol-mediated signaling GO:0048015 9.84 FGF1 FGF2 HGF MET
16 response to glucocorticoid GO:0051384 9.83 ADM CCL2 SPARC
17 aging GO:0007568 9.83 ADM CCL2 CTGF TGFB1 TIMP1
18 positive regulation of MAP kinase activity GO:0043406 9.81 FGF1 FGF2 TGFB1
19 phosphatidylinositol phosphorylation GO:0046854 9.81 FGF1 FGF2 HGF MET
20 inner ear development GO:0048839 9.8 SPARC TGFB1 TGFB2
21 response to peptide hormone GO:0043434 9.8 CTGF SPARC TIMP1
22 regulation of phosphatidylinositol 3-kinase signaling GO:0014066 9.78 FGF1 FGF2 HGF MET
23 response to progesterone GO:0032570 9.77 CCL2 TGFB1 TGFB2
24 epithelial to mesenchymal transition GO:0001837 9.76 HGF TGFB1 TGFB2
25 positive chemotaxis GO:0050918 9.74 FGF2 HGF MET
26 MAPK cascade GO:0000165 9.73 CCL2 FGF1 FGF2 HGF MET TGFB1
27 cell-cell junction organization GO:0045216 9.72 TGFB1 TGFB2
28 positive regulation of protein localization to nucleus GO:1900182 9.72 TGFB1 TGFB2
29 platelet degranulation GO:0002576 9.72 HGF SPARC TGFB1 TGFB2 TIMP1
30 positive regulation of blood vessel endothelial cell migration GO:0043536 9.71 FGF2 TGFB1
31 cartilage condensation GO:0001502 9.71 CTGF TGFB2
32 positive regulation of wound healing GO:0090303 9.71 CCL2 VTN
33 cell activation GO:0001775 9.71 TGFB1 TIMP1
34 animal organ regeneration GO:0031100 9.71 ADM CCL2 HGF TGFB1
35 hyaluronan catabolic process GO:0030214 9.7 FGF2 TGFB1
36 negative regulation of blood vessel endothelial cell migration GO:0043537 9.7 FGF2 TGFB1
37 negative regulation of immune response GO:0050777 9.7 TGFB1 TGFB2
38 positive regulation of collagen biosynthetic process GO:0032967 9.7 CCL2 CTGF TGFB1
39 pathway-restricted SMAD protein phosphorylation GO:0060389 9.69 TGFB1 TGFB2
40 glial cell migration GO:0008347 9.68 CCL2 TGFB2
41 hepatocyte growth factor receptor signaling pathway GO:0048012 9.68 HGF MET
42 salivary gland morphogenesis GO:0007435 9.67 TGFB1 TGFB2
43 positive regulation of cell division GO:0051781 9.67 FGF1 FGF2 TGFB1 TGFB2
44 SMAD protein import into nucleus GO:0007184 9.66 TGFB1 TGFB2
45 heart valve morphogenesis GO:0003179 9.65 TGFB1 TGFB2
46 positive regulation of sprouting angiogenesis GO:1903672 9.64 FGF1 FGF2
47 negative regulation of macrophage cytokine production GO:0010936 9.62 TGFB1 TGFB2
48 regulation of endothelial cell chemotaxis to fibroblast growth factor GO:2000544 9.58 FGF1 FGF2
49 negative regulation of hydrogen peroxide-mediated programmed cell death GO:1901299 9.56 HGF MET
50 wound healing GO:0042060 9.55 FGF2 SPARC TGFB1 TGFB2 TIMP1

Molecular functions related to Vitreoretinopathy, Neovascular Inflammatory according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein tyrosine kinase activity GO:0004713 9.71 FGF1 FGF2 HGF MET
2 cytokine activity GO:0005125 9.65 CCL2 FGF2 TGFB1 TGFB2 TIMP1
3 integrin binding GO:0005178 9.63 CTGF FGF1 VTN
4 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.62 FGF1 FGF2 HGF MET
5 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.46 FGF1 FGF2 HGF MET
6 type II transforming growth factor beta receptor binding GO:0005114 9.43 TGFB1 TGFB2
7 type III transforming growth factor beta receptor binding GO:0034714 9.37 TGFB1 TGFB2
8 heparin binding GO:0008201 9.35 CCL2 CTGF FGF1 FGF2 VTN
9 growth factor activity GO:0008083 9.17 CTGF FGF1 FGF2 HGF TGFB1 TGFB2

Sources for Vitreoretinopathy, Neovascular Inflammatory

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....